CNS Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CNSP CNS Pharmaceuticals Inc
SMTC Semtech Corp
EU enCore Energy Corp
CJET Chijet Motor Co Inc
LAKE Lakeland Industries Inc
JWEL Jowell Global Ltd
SMAR Smartsheet Inc
FOXA Fox Corp
SCVFF Scotch Creek Ventures Inc
VEDU Visionary Education Technology Holdings Group Inc

Health Care : Pharmaceuticals | Small Cap Value
Company profile

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Day's Change
-0.11 (-4.10%)
B/A Size
Day's High
Day's Low

Today's volume of 89,820 shares is on pace to be much lighter than CNSP's 10-day average volume of 1,263,378 shares.


DoorDash CEO and other co-founders to sell millions of shares, stock falls

8:09 am ET January 31, 2023 (MarketWatch)

By Levi Sumagaysay

Three top executives expect to sell at least 2 million shares apiece as options approach expiration date, company discloses

DoorDash Inc.'s three co-founders will sell millions of shares in the company beginning next month, the company disclosed Monday.

DoorDash (DASH) Chief Executive Tony Xu, Chief Technology Officer Andy Fang and Chief Product Officer Stanley Tang have unexercised stock options that expire on June 25, 2024, so they will sell up to 6.6 million shares among them.

The executives adopted trading plans in compliance with federal rules designed to avoid accusations of insider trading; because rules limit the number of shares that they can sell in any three-month period, the three executives will spread out their stock sales from February 2023 to June 2024.

Xu intends to sell up to 2.2 million shares of Class A common stock, while Fang and Tang intend to sell up to 2 million and 2.4 million shares each, respectively.

The company's announcement also noted that because the planned sales are related to options exercises, "we do not expect these dispositions to reduce Mr. Xu, Mr. Fang, and Mr. Tang's common stock holdings or voting power compared to current levels."

A DoorDash spokesman had no additional comment.

DoorDash shares closed 3.5% lower at $56.56 Monday, and fell more than 2% in after-hours trading. They have declined about 50% in the past 52 weeks but are up nearly 16% so far in 2023.

DoorDash's market capitalization is $22.76 billion. The company has 360.08 million shares outstanding and a public float of 262.41 million shares. The app-based delivery company is scheduled to report fourth-quarter earnings Feb. 16.

-Levi Sumagaysay


(END) Dow Jones Newswires

January 31, 2023 08:09 ET (13:09 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.